Guided Therapeutics

Guided Therapeutics EBIT per Share

The EBIT per Share of Guided Therapeutics (GTHP) as of Oct 18, 2026 is -0.03 USD. In the previous year, EBIT per Share was -0.03 USD — a change of -14.93% (higher).

EBIT per Share

-0.03USD

YoY

-14.93%

Last updated:

EBIT per Share of Guided Therapeutics is 2025 -0.03 USD. EBIT per Share of Guided Therapeutics was 2024 -0.03 USD. It decreases by -14.93% higher compared to the previous year.

The Guided Therapeutics EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2018
-0.58 USD
Jan 1, 2019
-0.28 USD
Jan 1, 2020
-0.08 USD
Jan 1, 2021
-0.17 USD
Jan 1, 2022
-0.07 USD
Jan 1, 2023
-0.06 USD
Jan 1, 2024
-0.03 USD
Jan 1, 2025
-0.03 USD
The Guided Therapeutics EBIT per Share history
YEAREBIT per ShareYoY
-0.03USD-14.93%
-0.03USD-49.35%
-0.06USD-6.84%
-0.07USD-60.30%
-0.17USD+115.74%
-0.08USD-71.64%
-0.28USD-51.32%
-0.58USD-98.85%
-50.38USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Guided Therapeutics Stock analysis

What does Guided Therapeutics do? Guided Therapeutics Inc, with ticker GTHP and ISIN US40171F5017, is a health care company headquartered in Norcross, Georgia. The company has 6 employees and went public on July 1, 1997. Guided Therapeutics focuses on developing medical devices, particularly utilizing biophotonic technology for cancer detection. The company's primary product is the LuViva Advanced Cervical Scan, a non-invasive device designed to detect cervical cancer and precancers. The LuViva device scans the cervix with light and analyzes the reflected and fluorescent light to provide results at the point of care. It serves as an alternative to conventional cervical cancer screening methods, targeting two main applications: as a screening tool and as a triage method for traditional screening processes. The company develops prototypes and conducts limited clinical studies using its biophotonic technology, which is central to its approach for detecting esophageal cancer. Guided Therapeutics operates within the health care sector and industry, with its website at https://www.guidedinc.com/. The company's current operational focus is on the development and marketing of the LuViva device, though it has also explored applications in esophageal cancer detection through biophotonic technology. Guided Therapeutics has a small workforce of six full-time employees, reflecting its current scale of operations. Guided Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Guided Therapeutics stock

EBIT per Share of Guided Therapeutics is -0.03 USD in 2025.

EBIT per Share of Guided Therapeutics changed from -0.03 USD to -0.03 USD, representing a -14.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Guided Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Guided Therapeutics

All Key Metrics — Guided Therapeutics